Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.0
4.1
Journals
CIMB
Special Issues
Early Molecular Diagnosis and Comprehensive Treatment of Tumors, 2nd Edition
cimb-logo
Submit to Special Issue Submit Abstract to Special Issue Review for CIMB Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Early Molecular Diagnosis and Comprehensive Treatment of Tumors, 2nd Edition

A Special Issue of Current Issues in Molecular Biology (ISSN 1467-3045) belonging to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 October 2026 | Viewed by 869

Editor

Dr. Chan-Yen Kuo

E-Mail Website
Guest Editor
Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan
Interests: oxidant stress; DNA damage and repair; microenvironment and tumorigenesis; nature products; inflammation and cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Timely and accurate diagnosis is crucial in improving cancer prognosis and guiding effective treatment strategies. This Special Issue will focus on the latest advancements in early molecular diagnostics and comprehensive treatment approaches in tumors. We aim to highlight innovative techniques, including liquid biopsy, next-generation sequencing (NGS), and novel biomarkers, that enhance early cancer detection and risk assessment.

Additionally, this Special Issue will explore integrative treatment modalities, combining targeted therapy, immunotherapy, precision medicine, and conventional approaches such as surgery, radiation, and chemotherapy. There will be a focus on the tumor microenvironment, the molecular mechanisms driving tumor progression, and emerging therapeutic strategies designed to improve patient outcomes.

By bringing together cutting-edge research and clinical applications, this Special Issue will provide a deeper understanding of tumor biology and pave the way for more effective personalized cancer treatments.

You can read the publications in the first volume here: https://www.mdpi.com/journal/cimb/special_issues/R8WT7615B6

Dr. Chan-Yen Kuo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • next-generation sequencing (NGS)
  • novel biomarkers
  • precision medicine
  • targeted therapy
  • immunotherapy
  • integrative treatment
  • personalized cancer treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 260 KB  
Article
Comparison of a Novel MRNA-Based Breast Cancer Subtyping Assay with PAM50 and Oncotype DX in Estrogen Receptor-Positive/HER2-Negative Breast Cancer: An Exploratory Age-Stratified Retrospective Cohort Study
by Till Wallrabenstein, Elena Diana Chiru, Martina Sonderegger, Simone Muenst, Christian Kurzeder and Marcus Vetter
Curr. Issues Mol. Biol. 2026, 48(9), 886; https://doi.org/10.3390/cimb48090886 - 31 Aug 2026
Viewed by 112
Abstract
Immunohistochemistry (IHC) of ER, PR, HER2, and Ki67 are established prognostic and predictive markers in breast cancer. Gene expression assays such as PAM50 and Oncotype DX are increasingly used for molecular subtyping and recurrence risk calculation. The APIS Breast Cancer Subtyping Kit (BCSK) [...] Read more.
Immunohistochemistry (IHC) of ER, PR, HER2, and Ki67 are established prognostic and predictive markers in breast cancer. Gene expression assays such as PAM50 and Oncotype DX are increasingly used for molecular subtyping and recurrence risk calculation. The APIS Breast Cancer Subtyping Kit (BCSK) quantitatively measures the mRNA expression of these markers (ER, PR, HER2, and Ki67) and includes a novel four-gene BCSK Proliferation Signature (PS) designed for subtype classification and risk stratification. This exploratory retrospective cohort study compares the BCSK with established molecular assays in an age-stratified cohort. We aimed to compare BCSK subtype classification in distinguishing Luminal A versus Luminal B subtypes with IHC and with PAM50. We have also aimed to assess correlations between the BCSK PS and the Oncotype DX Recurrence Score (RS) as well as the PAM50 Risk of Recurrence (ROR) score in patients stratified by age (<65 versus ≥65 years). Formalin-fixed, paraffin-embedded (FFPE) tumor specimens from 59 patients with ER+/HER2− breast cancer (33 < 65 years, 26 ≥ 65 years), diagnosed between 2020 and 2022 at the Cantonal Hospital Baselland and University Hospital Basel, were analyzed using IHC, BCSK, and PAM50 (Prosigna®). All patients received adjuvant therapy and had ODx scores available. Patient, disease and treatment characteristics were compared between age groups using the Fisher exact test. We assessed concordance in luminal subtype classification across IHC, BCSK, and PAM50 assays pairwise and stratified by age groups descriptively. We used Spearman’s rank correlation to examine associations between BCSK PS, RS, and ROR. Differences between age groups regarding PS were analyzed using the Mann–Whitney U test. In the ≥65-year cohort, subtype classification concordance between the BCSK and PAM50 was higher (84.6%) than in those aged <65-years (60.6%). In patients aged <65 years, the PS was significantly correlated with both RS (ρ = 0.5745, p < 0.0005) and ROR (ρ = 0.391, p = 0.024), whereas RS and ROR were not significantly correlated. In patients ≥65 years, PS correlated significantly with ROR (ρ = 0.603, p = 0.001), while there were no significant correlations between PS and RS (ρ = 0.134, p = 0.514) and between RS and ROR (ρ = 0.149, p = 0.466). Median PS values did not significantly differ between age groups (0.589 versus 0.602, p = 0.97). In this exploratory retrospective age-stratified analysis, the BCSK demonstrated descriptive concordance with PAM50 subtype classifications, especially in patients aged ≥65 years. PS showed significant but moderate correlation with the established molecular recurrence scores RS and ROR, however these differed across age groups. Our findings should be considered hypothesis-generating because this study did not include outcome metrics and was based on a relatively small cohort. Larger prospective studies incorporating clinical outcomes are necessary to determine the diagnostic and prognostic utility as well as comparative cost-effectiveness of the BCSK and its utility across age groups. Full article
(This article belongs to the Special Issue Early Molecular Diagnosis and Comprehensive Treatment of Tumors, 2nd Edition)

Review

Jump to: Research

28 pages, 4493 KB  
Review
The Mechanism and Pathways of Formation and Modification of Salivary Metabolic Profile in Cancer
by Elena I. Dyachenko and Lyudmila V. Bel’skaya
Curr. Issues Mol. Biol. 2026, 48(7), 728; https://doi.org/10.3390/cimb48070728 - 16 Jul 2026
Viewed by 488
Abstract
Saliva is a promising diagnostic fluid for studying diseases, including cancer. Saliva composition can reflect both local processes occurring in the oral cavity and systemic changes associated with distant tumors. This review examines changes in salivary electrolyte, amino acid, lipid, and cytokine profiles, [...] Read more.
Saliva is a promising diagnostic fluid for studying diseases, including cancer. Saliva composition can reflect both local processes occurring in the oral cavity and systemic changes associated with distant tumors. This review examines changes in salivary electrolyte, amino acid, lipid, and cytokine profiles, tumor markers, and the oral microbiome in cancer. Collectively, these aspects reflect metabolic, inflammatory, immune, secretory, and tumor-associated processes. Metabolites can enter saliva via the salivary glands, systemic circulation, gingival fluid, extracellular vesicles, and oral cells, as well as directly from the site of disease during localized pathological processes. In tumors not localized in the oral cavity, changes in saliva composition are more often associated with systemic inflammation, altered oral microbiome, metabolic reprogramming, oxidative stress, and tumor-associated exosomes. Individual metabolites have limited specificity and cannot be used as independent diagnostic indicators. A comprehensive multimarker analysis of saliva is of greatest value. This approach can facilitate early diagnosis, identify the risk of disease development and progression, monitor therapy, and understand the biological changes associated with the pathological process, including tumors. Full article
(This article belongs to the Special Issue Early Molecular Diagnosis and Comprehensive Treatment of Tumors, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop